
[EPISODE 25] Adam Stasio Talks, Large Data Sets, Breaking Down Problems, and Tech-Driven Solutions
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
This is the final blog in our three-part flow cytometry series. Part 1 highlighted the broad application of flow cytometry
In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
PCR platforms and Good Manufacturing Practices (GMP) certification further enhance European service offerings HAMBURG, GERMANY and DURHAM, NC, May 8,
BioAgilytix continues to build leadership in Europe. Hamburg, Germany April 3, 2023 – BioAgilytix, a leading global bioanalytical laboratory, today
This is the final blog in our three-part flow cytometry series. Part 1 highlighted the broad application of flow cytometry
As we continue our blog series on flow cytometry, we’ll now dive into how this powerful capability supports multiple types
Analytical testing of therapeutic compounds often requires data at the single-cell level. Flow cytometry is a versatile technology that can
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
This is the final blog in our three-part flow cytometry series. Part 1 highlighted the broad application of flow cytometry
In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
PCR platforms and Good Manufacturing Practices (GMP) certification further enhance European service offerings HAMBURG, GERMANY and DURHAM, NC, May 8,
BioAgilytix continues to build leadership in Europe. Hamburg, Germany April 3, 2023 – BioAgilytix, a leading global bioanalytical laboratory, today
This is the final blog in our three-part flow cytometry series. Part 1 highlighted the broad application of flow cytometry
As we continue our blog series on flow cytometry, we’ll now dive into how this powerful capability supports multiple types
Analytical testing of therapeutic compounds often requires data at the single-cell level. Flow cytometry is a versatile technology that can
As a leader in specialized and complex bioassay development and testing, BioAgilytix combines state-of-the-art cell-based assay facilities with a veteran team of scientists well-versed in the quality and regulatory demands of biological assay development to support customers innovating in the areas of biologics, biosimilars, and biobetters.
BioAgilytix has a proven track record of effectively developing, qualifying and validating a diverse range of bioassays to meet stringent scientific and regulatory demands across numerous industries and disease states.
Use the paragraphs below to learn what a bioassay is, how it can be used to effectively determine concentration and potency of a biological substance, the types of platforms that best support bioassay needs, and how BioAgilytix brings a differentiated level of expertise to the bioassay services we provide.
Our Bioassay Services Include:
Industries We Specialize In:
Here we will outline what a bioassay is, and how a bioassay can be used to effectively determine the concentration and potency of a biological substance. We’ll also discuss the types of platforms that best support bioassay needs and how BioAgilytix brings a differentiated level of expertise to the bioassay services we provide.
Bioassay is a biochemical test that calculates the relative potency of a sample compound to a standard compound. By definition, a bioassay is the “determination of the relative strength of a substance (as a drug) by comparing its effect on a test organism with that of a standard preparation.” Bioassays are used to measure the biological activity and effects of a substance, like a hormone or drug, on a living organism such as a living plant (in vivo) or tissue or cell (in vitro).
Bioassay services are most often employed to determine the concentration or purity of substances including vitamin, hormone, or plant growth factor by measuring their effect on tissue, cells, enzymes, or receptors. The general approach involves measuring the biological response of the live material at several doses, to understand the dose-response relation.
As such, the advantage of the bioassay testing procedure is that it can help determine both the concentration and potency of a sample, which is necessary for regulatory submission and lot release testing of biopharmaceutical products.
The primary purposes of bioassays are to measure the pharmacological activity of new or chemically undefined substances, as well as to determine side-effect profiles, including toxicity.
Bioassays are key in determining the potency and stability of a drug substance or product in order to establish its safety and efficacy profile. Today, they are an important component in effectively controlling the quality of biopharmaceuticals for lot release testing and manufacture.
BioAgilytix’s premier GMP laboratory is built to support the full range of bioanalytical requirements, from custom bioassay development to lot release testing, and stability testing under GLP and GMP standards.
The scientists at BioAgilytix are responsible for lead optimization and mechanism-of-action studies that have led to the discovery of several key drugs that are on the market today, as well as a number of promising clinical candidates.
Having supported the bioanalysis of numerous therapeutics now successfully brought to market, we intrinsically know the types of challenges to anticipate in each phase. Our team works proactively to mitigate your risk and to solve problems quickly so you can bring your life-saving innovations to market faster.
Our commitment is to see you succeed! This is what makes BioAgilytix the go-to scientific partner for those seeking to improve patient outcomes with more potent and effective biologic therapeutics across disease states, from research to drug development.
BioAgilytix’s premier GMP laboratory is built to support the full range of bioanalytical requirements, from custom bioassay development to lot release testing and stability testing under GLP and GMP standards.
See how we apply our specialized large molecule expertise to help solve your bioanalytical challenges.
Discover the 8 key selection criteria you should consider when evaluating a bioanalytical CRO to ensure a successful partnership.
There are a number of innovative technologies and platforms that can be used to help automate bioassay testing processes and yield greater throughput, speed, reliability, and reproducibility.
BioAgilytix leverages a unique breadth of platforms to support the delivery of its bioassay services, including ELISA, MSD-ECL, ProteinSimple ELLA and Flow Cytometry. For a full listing of the technology platforms leveraged by BioAgilytix, click here.
By selecting the platform to optimally support each bioassay’s specific parameters, we are able to perform robust, timely analysis related to:
With more than half of our scientific staff boasting over 15 years of experience performing complex bioassays – having cultured over 200 cell lines – BioAgilytix leads the industry in the development and testing of cell-based assays to GLP and GMP standards.
We never let a specialized or demanding bioassay requirement stall our customers’ speed of innovation, and work scientist to scientist to solve even the most challenging bioanalytical assay needs with responsive service and seasoned expertise.
Our scientists can help you choose the method that will best support your distinct bioassay parameters. We understand the key considerations that should be assessed as part of your bioassay system selection, and will carefully weigh the advantages and disadvantages of each to select the optimal model.
From supporting scientific breakthroughs or developing novel therapeutic drugs, BioAgilytix has proven our ability to efficiently advance large molecule innovations no matter the complexity of the bioassay demands. Our strategy is driven by quality science that yields quality results.
Whether you’re a leading global company or an organization on the rise, BioAgilytix can supplement your internal resources to extend your bioanalytical capabilities or take them over entirely.
Choose BioAgilytix for Your Bioassay Development and Testing
Rely on the scientists at BioAgilytix. We are responsible for lead optimization and mechanism-of-action studies that have supported the discovery of several key drugs on the market today, as well as multiple promising clinical candidates, that can support your unique project requirements. Let us help you bring clarity to the complexities of bioassays in the development of life-changing innovations.
Let us help you bring clarity to the complexities of bioassays in the development of life-changing innovations.
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
37 Kent St, Woolloongabba
Queensland, 4102, Australia
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
37 Kent St,Woolloongabba
Queensland, 4102, Australia
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
85 Commercial Road, Melbourne
Victoria, 3004, Australia
+61 3 9282 2184
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
85 Commercial Road, Melbourne
Victoria, 3004, Australia
+61 3 9282 2184
Copyright © 2023 BioAgilytix Labs.
All rights reserved.
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
5927 S. Miami Blvd. Suite 100
Morrisville, NC 27703
919-381-6097
Fax 919-381-6099
1320 Soldiers Field Road
Boston, MA, 02135
Office 617-456-0700
Fax 617-456-0701
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
37 Kent St, Woolloongabba
Queensland, 4102, Australia
85 Commercial Road, Melbourne
Victoria, 3004, Australia
03 9282 2184
Copyright © 2023 BioAgilytix Labs.
All rights reserved.
Terms of Use | Privacy Notice
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
5927 S. Miami Blvd. Suite 100
Morrisville, NC 27703
919-381-6097
Fax 919-381-6099
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
37 Kent St,Woolloongabba
Queensland, 4102, Australia
85 Commercial Road, Melbourne
Victoria, 3004, Australia
03 9282 2184
Copyright © 2023 BioAgilytix Labs.
All rights reserved.